Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Growth in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 47,100 shares, a growth of 20.8% from the May 31st total of 39,000 shares. Currently, 10.7% of the shares of the stock are short sold. Based on an average daily volume of 28,400 shares, the days-to-cover ratio is presently 1.7 days.

Windtree Therapeutics Stock Down 2.4 %

Shares of NASDAQ WINT opened at $3.21 on Friday. The stock has a market capitalization of $1.89 million, a price-to-earnings ratio of -0.09 and a beta of 0.62. Windtree Therapeutics has a 52 week low of $2.89 and a 52 week high of $30.06. The firm has a 50-day moving average price of $3.96 and a 200 day moving average price of $6.83.

Windtree Therapeutics (NASDAQ:WINT) last posted its quarterly earnings results on Tuesday, April 16th. The company reported ($13.31) earnings per share (EPS) for the quarter. Equities research analysts expect that Windtree Therapeutics will post -24.93 EPS for the current fiscal year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.